For Research Use Only. Not for human consumption.

Product Identifier: PT-141 (Bremelanotide) — Melanocortin Receptor Analog

Application Framework: Synthesized strictly as a bulk chemical reagent for institutional laboratory experimentation, in vitro analytical research examining melanocortin receptor binding kinetics (MC1R, MC3R, MC4R), cyclic peptide conformation studies, and ACTH/MSH analog pathway analysis at the molecular level.

Regulatory Notice: Bremelanotide exists as an FDA-approved pharmaceutical product (Vyleesi®) for a specific human indication. This listing refers solely to the unformulated research-grade chemical compound supplied exclusively for in vitro analytical investigation in institutional laboratory settings. This product is not the FDA-approved pharmaceutical formulation, is not sterile-filled in pharmaceutical-grade vials, and is not intended for any form of human administration whatsoever.

Analytical Specifications

• Purity Level: 98%+ verified via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS).
• Structure: Cyclic hepta-peptide melanocortin receptor agonist; alpha-MSH analog with cyclic lactam bridge.
• Form: Lyophilized solid matrix optimized for in vitro analytical research and molecular stability.
• Packaging Infrastructure: Dispatched in specialized, factory-sealed grid containment boxes to secure the chain of custody.

Mandatory Institutional Terms

Aegis Research Solutions does not provide consumer-facing retail packaging. Materials are distributed exclusively for research mandates within a designated facility. Buyers assume all regulatory and compliance responsibility within their respective jurisdictions. Not intended for human therapeutic, diagnostic, or clinical applications. Not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.